Precision medicine firm Tempus has launched two new tests to help identify patients with HER2- or FOLR1-expressing tumors who may be eligible for targeted therapies such as antibody-drug conjugates.
According to a statement from the company, HER2 and FOLR1 testing for solid-tumor cancers by immunohistochemistry (IHC) is now available as an add-on to the company's xT or xR next-generation sequencing assays.
The two IHC tests are recommended in clinical guidelines for several cancer types and may be ordered for other cancer types at the clinician's discretion. FOLR1 testing is recommended for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, Tempus said.
Additionally, the firm noted that the recent approval by the U.S. Food and Drug Administration of trastuzumab deruxtecan (Enhertu) highlights the necessity of HER2 testing in guiding therapy decisions. Enhertu was approved in April for the treatment of unresectable or metastatic HER2-positive (IHC 3+) solid tumors in adult patients who have received prior systemic treatment and have no satisfactory alternative treatment options.
